The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LYEL | +32.13% | N/A | N/A | -93% |
| S&P | +13% | +86.41% | +13.26% | +60% |
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.02M | -55.9% |
| Gross Profit | -$2.55M | 45.1% |
| Gross Margin | -17006.67% | -3342.0% |
| Market Cap | $311.99M | -11.9% |
| Market Cap / Employee | $1.04M | 0.0% |
| Employees | 300 | 33.9% |
| Net Income | -$38.85M | 12.9% |
| EBITDA | -$36.28M | 22.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $123.58M | 23.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.29M | -13.9% |
| Short Term Debt | $8.79M | 23.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.41% | -34.6% |
| Return On Invested Capital | -36.92% | -9.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$28.64M | 18.4% |
| Operating Free Cash Flow | -$28.58M | 18.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.49 | 0.47 | 0.39 | 0.81 | 20.76% |
| Price to Sales | 2796.47 | 2442.50 | 2179.50 | 7235.91 | 28.88% |
| Price to Tangible Book Value | 6.19 | 8.29 | 0.39 | 0.81 | -93.96% |
| Enterprise Value to EBITDA | 2.42 | 1.58 | 2.40 | -0.83 | -236.87% |
| Return on Equity | -66.1% | -71.2% | -76.6% | -75.8% | 128.06% |
| Total Debt | $58.97M | $57.09M | $46.60M | $53.07M | -9.39% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
